Ownership and insider activity for Sana Biotechnology, Inc. (SANA): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Sana Biotechnology, Inc. is a biotechnology firm focused on creating treatments using engineered cells. The company develops advanced ex vivo and in vivo cell engineering platforms to address a range of conditions with significant unmet medical needs, including various cancers, diabetes, central nervous system disorders, cardiovascular diseases, and genetic illnesses.
Price
| Price | $2.92 |
| Market Cap | $813M |
| Exchange | NASDAQ |
| Country | US |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-08-26 | PATEL DHAVALKUMAR DHIRAJLAL | M-Exempt | 125,000 | |
| 2026-08-26 | PATEL DHAVALKUMAR DHIRAJLAL | M-Exempt | 125,000 | |
| 2026-08-27 | PATEL DHAVALKUMAR DHIRAJLAL | F-InKind | 41,158 | $169K |
| 2026-07-06 | Bishop Hans Edgar | A-Award | 6,297 | |
| 2026-06-04 | Yang Patrick Y | A-Award | 90,000 | $266K |
| 2026-06-04 | Rosiello Robert L. | A-Award | 90,000 | $266K |
| 2026-06-04 | Seitz Michelle | A-Award | 90,000 | $266K |
| 2026-06-04 | REICIN ALISE | A-Award | 90,000 | $266K |
| 2026-06-04 | Mulligan Richard | A-Award | 90,000 | $266K |
| 2026-06-04 | Bishop Hans Edgar | A-Award | 90,000 | $266K |
Balance Sheet (10y)
| Year | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $30.6M | $80.0M | $124.8M | $253.0M | $176.8M | $133.5M | $127.6M | $71.9M |
| Short-term Investments | 0 | $59.0M | $253.5M | $298.0M | $247.2M | $71.7M | $24.9M | $66.5M |
| Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | $32.6M | $144.3M | $384.5M | $558.1M | $444.4M | $213.5M | $160.8M | $148.7M |
| Property, Plant & Equipment | $585000 | $68.8M | $109.9M | $161.8M | $159.4M | $145.6M | $135.3M | $65.2M |
| Goodwill | 0 | $140.6M | $140.6M | $140.6M | $140.6M | $140.6M | $140.6M | $140.6M |
| Intangible Assets | 0 | $59.2M | $59.2M | $59.2M | $59.2M | $59.2M | $59.2M | $59.2M |
| Total Assets | $34.3M | $415.2M | $730.3M | $1.13B | $822.7M | $565.3M | $501.0M | $416.9M |
| Accounts Payable | $289000 | 0 | $2.3M | $2.2M | $2.9M | $4.1M | $5.2M | $1.7M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Liabilities | $1.8M | $19.3M | $31.5M | $99.2M | $111.5M | $64.5M | $45.4M | $78.7M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | $47.5M | $557.7M | $1.15B | $400.9M | $323.4M | $277.8M | $250.5M | $256.0M |
| Retained Earnings | -$13.2M | -$144.1M | -$429.4M | -$785.4M | -$1.05B | -$1.34B | -$1.60B | -$1.85B |
| Total Equity | -$13.2M | -$142.5M | -$421.2M | $728.5M | $499.3M | $287.5M | $250.5M | $160.9M |
| Total Debt | 0 | $47.7M | $71.9M | $110.9M | $108.3M | $104.1M | $94.2M | $78.9M |
| Net Debt | -$30.6M | -$91.3M | -$306.4M | -$440.1M | -$315.7M | -$101.1M | -$58.3M | -$59.5M |
| Working Capital | $30.8M | $124.9M | $353.0M | $458.9M | $332.9M | $149.0M | $115.4M | $70.0M |
Financial Health
| Debt / Equity | 0.48 |
| Current Ratio | 1.38 |
| Piotroski F-Score | 2 |
| Altman Z-Score | -5.10 |
Profitability
| Return on Equity | -134.49% |
| Return on Invested Capital | -64.54% |
| Return on Assets | -49.09% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: DNTH · INBX · KOD · NKTR · NRIX · OCS · PHAT
Explore sector: Healthcare · Biotechnology
More sections of SANA: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks